Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9837
Title: Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy.
Authors: Christophi, Christopher;Nikfarjam, Mehrdad;Malcontenti-Wilson, Caterina;Muralidharan, Vijayaragavan
Affiliation: Department of Surgery, University of Melbourne, Austin Hospital, LTB 8, Studley Road, Heidelberg, 3084, Melbourne, Victoria, Australia. surgery-armc@unimelb.edu.au
Issue Date: 29-Sep-2004
Citation: World Journal of Surgery 2004; 28(10): 987-94
Abstract: In situ ablation of colorectal cancer (CRC) liver metastases is an accepted form of treatment for selected patients. It is associated with low morbidity and mortality and increases the number of patients who may benefit from therapy compared to resection alone. This study assesses the impact of interstitial laser thermotherapy (ILT) on local tumor control and long-term survival in patients with unresectable CRC liver metastases. Percutaneous ILT was performed in patients with unresectable CRC liver metastases between January 1992 and December 1999 using a bare-tip quartz fiber connected to an Nd:YAG laser source. This was prior to the routine use of a diffusing fiber for ablative therapy. Treatment was monitored with real-time ultrasonography. Tumors were considered unresectable based on their anatomic location or the extent of liver involvement. Patients with extrahepatic disease, more than five liver metastases, or tumors larger than 10 cm in diameter were excluded from this study. Local tumor control was assessed by dynamic computed tomography (CT) 6 months after therapy. Long-term follow-up was undertaken, and the impact of various factors on survival was analyzed. Eighty patients with a mean age of 63.8 years were suitable for ILT. In total, 168 liver tumors with a median diameter of 5 cm (range 1-10 cm) were so treated. There were no procedure-related deaths. The overall complication rate was 16%, with all cases managed conservatively. Bradycardia (n = 5), pneumothorax (n = 3), and persistent pyrexia (n = 3) were the most common complications. Complete tumor ablation was noted in 67% of patients assessed by CT 6 months following the initial therapy. Median follow-up was 35 months (range 4-96 months), with 10 patients alive at the end of this period. Altogether there were 67 deaths, which were related to hepatic disease in 55 cases and to extrahepatic disease in 9; they were unrelated to malignancy in 3 others. Three patients were excluded from follow-up after ILT down-staging of tumors that allowed complete surgical resection. The median disease-free survival of patients treated by ILT was 24.6 months, with a 5-year survival of 3.8%. Poor tumor differentiation and the presence of more than two hepatic metastases were associated with lower overall survival (p < 0.01). Fourteen patients treated by ILT for postoperative hepatic recurrences had the best outcome, with a median overall survival of 36.3 months and a 5-year survival of 17.2%. Percutaneous ILT is a minimally invasive, safe, effective technique that appears to improve overall survival in specific patients with unresectable CRC liver metastases, compared to the natural history of untreated disease reported in the literature.
Internal ID Number: 15573253
URI: http://ahro.austin.org.au/austinjspui/handle/1/9837
DOI: 10.1007/s00268-004-7202-1
URL: http://www.ncbi.nlm.nih.gov/pubmed/15573253
Type: Journal Article
Subjects: Aged
Colorectal Neoplasms.pathology
Disease-Free Survival
Female
Humans
Hyperthermia, Induced.methods
Laser Therapy
Liver Neoplasms.mortality.secondary.therapy
Male
Survival Analysis
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
15573253.pdf57.24 kBAdobe PDFView/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.